Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
Susana Sainz de la Maza(Universidad de Alcalá), Luisa María Villar(Evidence (Italy)), Rubén Ballester-González(Universidad de Alcalá), Roberto Pariente(Universidad de Alcalá), Paulette Esperanza Walo-Delgado(Universidad de Alcalá), Enric Monreal(Hospital Universitario Ramón y Cajal), Alexander Rodero-Romero(Universidad de Alcalá), Jaime Masjuán(Universidad de Alcalá), Noelia Villarrubia(Universidad de Alcalá), Fernando Rodríguez‐Jorge(Universidad de Alcalá), Mario Rodríguez-Domínguez(Instituto Cajal), Lucienne Costa‐Frossard(Universidad de Alcalá), Beatriz Romero‐Hernández(Instituto de Salud Carlos III), Juan Luis Chico‐García(Universidad de Alcalá)
Cited by 7
Related Papers
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study
|European Journal of Neurology|2020|385
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
|Critical Care|2009|382